Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Fourth biennial BHGI Global Summit on International Breast Health

The Breast Health Global Initiative and the Latin American & Caribbean Society of Medical Oncology will convene the fourth biennial BHGI Global Summit on International Breast Health June 9-11, 2010 in Chicago, bringing together collaborating national and international organizations to address the optimization of breast health care delivery in limited-resource countries.

31 Mar 2010

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

The European Hematology Association and the American Society of Hematology have selected Ingmar Bruns, MD, as the seventh recipient of the EHA-ASH Research Exchange Award, which serves to strengthen ties between North American and European scientific communities.

31 Mar 2010

Astellas Pharma extends all-cash tender offer of OSI Pharmaceuticals

Astellas Pharma Inc. announced today that it has extended its all-cash tender offer for $52 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals to 11:59 p.m. New York City time on Friday, April 23, 2010, unless further extended.

31 Mar 2010

Roche Diagnostics' CoaguChek XS Plus system granted CLIA-waived status

Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) has granted CLIA-waived status to the CoaguChek® XS Plus system, a point-of-care anticoagulation monitor that offers connectivity and data management tools to help healthcare professionals manage PT/INR (blood clotting time) testing.

From Roche Sequencing and Life Science 31 Mar 2010

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai.

31 Mar 2010

EvoLife Laboratories introduces cancer care products in USA

EvoLife Laboratories, a world leader in the development of products for skin, oral, nail, hair, hygiene care specifically designed for cancer patients undergoing chemotherapy and radiotherapy, announced the launch of its products in USA.

31 Mar 2010

Devicor offers to acquire EES Breast Care business

Ethicon Endo-Surgery, Inc. (EES), a Johnson & Johnson company, today announced it has received an irrevocable, unconditional offer from Devicor Medical Products (Devicor), a portfolio company of GTCR Golder Rauner, LLC, (GTCR), to acquire its Breast Care business. The EES Breast Care business sells products designed to help doctors diagnose breast cancer at early stages, while minimizing patient discomfort. Financial terms of the offer are not being disclosed.

31 Mar 2010

Top neurologists to receive 2010 AAN Alliance Awards

The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.

31 Mar 2010

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

FDA issues Complete Response Letter for CERTRIAD NDA

AstraZeneca and Abbott announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for the New Drug Application (NDA) for CERTRIAD™ (rosuvastatin / fenofibric acid delayed release) Capsules.

31 Mar 2010

Hospira acquires Orchid's injectables formulations business

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has completed the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million.

31 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

StockPreacher.com releases investment report on MDRNA

StockPreacher.com announces an investment report featuring drug developer MDRNA Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

30 Mar 2010

Appeals court ruling clears way for Enzo Biochem to pursue claim for substantial damages against Applera

Enzo Biochem Inc. said today that a decision released Friday by the Court of Appeals for the Federal Circuit reversing a district court's summary judgment will enable the Company to pursue a claim for substantial damages against Applera Corporation, now Life Technologies Corporation. The Court of Appeals vacated the lower court's judgments of invalidity on United States Patent Nos. 5,328,824 and 5,449,767.

30 Mar 2010

Breast cancer patients undertreated, essential radiation after mastectomy not performed

While radiation therapy is common after breast conserving surgery, it's much less frequent after mastectomy, even among women for whom it would have clear life-saving benefit. This is according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

30 Mar 2010

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Silence Therapeutics plc today announced that the company and Dainippon Sumitomo Pharma Co., Ltd. have agreed to an expansion of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in August 2009, the companies are leveraging Silence's proprietary siRNA molecules and multiple lipid delivery and targeting technologies to demonstrate functional delivery of RNA interference (RNAi) therapeutics to specific disease targets in the body.

30 Mar 2010

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.

30 Mar 2010

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.

30 Mar 2010

Tomato genes could be used as future treatment in gene therapy: Study

Tomato genes could be used as a future treatment in gene therapy, according to new research results from Lund University.

30 Mar 2010

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.

30 Mar 2010

Oncology News and Research

Further Reading

Fourth biennial BHGI Global Summit on International Breast Health

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

Astellas Pharma extends all-cash tender offer of OSI Pharmaceuticals

Roche Diagnostics' CoaguChek XS Plus system granted CLIA-waived status

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

EvoLife Laboratories introduces cancer care products in USA

Devicor offers to acquire EES Breast Care business

Top neurologists to receive 2010 AAN Alliance Awards

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

FDA issues Complete Response Letter for CERTRIAD NDA

Hospira acquires Orchid's injectables formulations business

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

StockPreacher.com releases investment report on MDRNA

Appeals court ruling clears way for Enzo Biochem to pursue claim for substantial damages against Applera

Breast cancer patients undertreated, essential radiation after mastectomy not performed

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Tomato genes could be used as future treatment in gene therapy: Study

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News